NO20014131L - Epitopes or mimotopes derived from C-epsilon-3 or C-epsilon-4 domains from IgE, antagonists thereof, and derester therapeutic applications - Google Patents
Epitopes or mimotopes derived from C-epsilon-3 or C-epsilon-4 domains from IgE, antagonists thereof, and derester therapeutic applicationsInfo
- Publication number
- NO20014131L NO20014131L NO20014131A NO20014131A NO20014131L NO 20014131 L NO20014131 L NO 20014131L NO 20014131 A NO20014131 A NO 20014131A NO 20014131 A NO20014131 A NO 20014131A NO 20014131 L NO20014131 L NO 20014131L
- Authority
- NO
- Norway
- Prior art keywords
- epsilon
- ige
- epitopes
- domains
- derester
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Abstract
Foreliggende oppfinnelse vedrører nye medikamenter for behandling, forebygging og forbedring av allergisk sykdom. Spesielt er de nye medikamentene epitoper eller mimo-toper avledet fra Ce3- eller Ce4-domenene til IgE. Disse nye regionene kan være mål for både passiv og aktiv immunprofylakse eller immunterapi. Oppfinnelsen vedrører ytterligere fremgangsmåter for produksjon av medikamenter, farmasøytisk sammenset-ning inneholdende disse og deres anvendelse i medisin. Også et aspekt for foreliggende oppfinnelse er ligander, spesielt monoklonale antistoffer, som er istand til å binde til IgE-regionene i den foreliggende oppfinnelsen, og deres anvendelse i medisin som passiv immunterapi eller immunprofylakse.The present invention relates to new medicaments for the treatment, prevention and improvement of allergic disease. In particular, the new drugs are epitopes or mimo-tops derived from the Ce3 or Ce4 domains of IgE. These new regions may be targets for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to processes for the manufacture of medicaments, pharmaceutical compositions containing them and their use in medicine. Also an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding to the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9904408.3A GB9904408D0 (en) | 1999-02-25 | 1999-02-25 | Vaccine |
GBGB9917144.9A GB9917144D0 (en) | 1999-07-21 | 1999-07-21 | Vaccine |
GBGB9918606.6A GB9918606D0 (en) | 1999-08-07 | 1999-08-07 | Novel peptides |
GBGB9918599.3A GB9918599D0 (en) | 1999-08-07 | 1999-08-07 | Novel peptides |
GBGB9918601.7A GB9918601D0 (en) | 1999-08-07 | 1999-08-07 | Novel peptides |
GBGB9918598.5A GB9918598D0 (en) | 1999-08-07 | 1999-08-07 | Novel peptides |
GBGB9918604.1A GB9918604D0 (en) | 1999-08-07 | 1999-08-07 | Novel peptides |
GBGB9925618.2A GB9925618D0 (en) | 1999-10-29 | 1999-10-29 | Vaccine |
PCT/EP2000/001456 WO2000050461A1 (en) | 1999-02-25 | 2000-02-22 | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20014131D0 NO20014131D0 (en) | 2001-08-24 |
NO20014131L true NO20014131L (en) | 2001-10-02 |
Family
ID=27571340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20014131A NO20014131L (en) | 1999-02-25 | 2001-08-24 | Epitopes or mimotopes derived from C-epsilon-3 or C-epsilon-4 domains from IgE, antagonists thereof, and derester therapeutic applications |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1155038A1 (en) |
JP (1) | JP2002537403A (en) |
KR (1) | KR20020007314A (en) |
CN (1) | CN1520423A (en) |
AR (1) | AR029619A1 (en) |
AU (1) | AU3281100A (en) |
CA (1) | CA2363641A1 (en) |
CO (1) | CO5231139A1 (en) |
CZ (1) | CZ20013081A3 (en) |
HK (1) | HK1043134A1 (en) |
HU (1) | HUP0105490A3 (en) |
IL (1) | IL145025A0 (en) |
MX (1) | MXPA01008612A (en) |
NO (1) | NO20014131L (en) |
NZ (1) | NZ513680A (en) |
PL (1) | PL350992A1 (en) |
TR (1) | TR200102493T2 (en) |
WO (1) | WO2000050461A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2206701A (en) * | 1999-12-21 | 2001-07-03 | Acambis Research Limited | A reversible linkage technology for controlled conjugation |
WO2001085208A2 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
GB0026334D0 (en) * | 2000-10-27 | 2000-12-13 | Smithkline Beecham Biolog | Vaccine |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7320793B2 (en) * | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
JP2003047482A (en) * | 2001-05-22 | 2003-02-18 | Pfizer Prod Inc | IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY |
ES2335979T3 (en) | 2001-09-14 | 2010-04-07 | Cytos Biotechnology Ag | IMMUNOSTIMULATOR CPG PACKAGING IN VIRUS SIMILAR PARTICLES: PREPARATION METHOD AND ITS USE. |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
GB0209878D0 (en) * | 2002-04-30 | 2002-06-05 | Glaxosmithkline Biolog Sa | Vaccine |
US7138252B2 (en) | 2002-07-17 | 2006-11-21 | Cytos Biotechnology Ag | Molecular antigen arrays |
KR101228376B1 (en) | 2002-07-18 | 2013-01-31 | 사이토스 바이오테크놀로지 아게 | Hapten-carrier conjugates and uses thereof |
DE60336902D1 (en) | 2002-07-19 | 2011-06-09 | Cytos Biotechnology Ag | VACCINE COMPOSITIONS CONTAINING AMYLOID BETA 1-6 ANTIGENARRAYS |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
AU2004224762B2 (en) | 2003-03-26 | 2009-12-24 | Kuros Us Llc | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
KR20070008578A (en) * | 2004-02-02 | 2007-01-17 | 타녹스 인코퍼레이티드 | Identification of novel ige epitopes |
GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
US8137670B2 (en) | 2005-09-29 | 2012-03-20 | Medimmune, Llc | Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells |
EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
SG172696A1 (en) | 2006-06-12 | 2011-07-28 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
EP2376108B1 (en) | 2008-12-09 | 2017-02-22 | Pfizer Vaccines LLC | IgE CH3 PEPTIDE VACCINE |
CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
WO2013191166A1 (en) * | 2012-06-18 | 2013-12-27 | 日本全薬工業株式会社 | IgE PEPTIDE VACCINE |
KR102031845B1 (en) * | 2018-04-06 | 2019-10-15 | 주식회사 에스엘에스바이오 | A novel epitope of immunoglobulin e, antibody binding thereto and a kit comprising above antibody for analysis of immunoglobulin e |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02229200A (en) * | 1989-02-28 | 1990-09-11 | Dainippon Pharmaceut Co Ltd | Peptide having anti-allergic activity |
ES2296839T3 (en) * | 1991-08-14 | 2008-05-01 | Genentech Inc. | IMMUNOGLOBULIN VARIANTS FOR SPECIFIC FC-EPSILON RECEIVERS. |
KR100584051B1 (en) * | 1996-03-01 | 2006-05-30 | 노파르티스 아게 | Peptide Immunogens for Vaccination against and Treatment of Allergy |
WO1998024808A2 (en) * | 1996-12-06 | 1998-06-11 | THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH | INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE |
TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
-
2000
- 2000-02-22 TR TR2001/02493T patent/TR200102493T2/en unknown
- 2000-02-22 JP JP2000601039A patent/JP2002537403A/en active Pending
- 2000-02-22 CN CNA008067562A patent/CN1520423A/en active Pending
- 2000-02-22 KR KR1020017010940A patent/KR20020007314A/en not_active Application Discontinuation
- 2000-02-22 IL IL14502500A patent/IL145025A0/en unknown
- 2000-02-22 CA CA002363641A patent/CA2363641A1/en not_active Abandoned
- 2000-02-22 PL PL00350992A patent/PL350992A1/en not_active Application Discontinuation
- 2000-02-22 EP EP00910690A patent/EP1155038A1/en not_active Withdrawn
- 2000-02-22 HU HU0105490A patent/HUP0105490A3/en unknown
- 2000-02-22 CZ CZ20013081A patent/CZ20013081A3/en unknown
- 2000-02-22 WO PCT/EP2000/001456 patent/WO2000050461A1/en not_active Application Discontinuation
- 2000-02-22 MX MXPA01008612A patent/MXPA01008612A/en unknown
- 2000-02-22 AU AU32811/00A patent/AU3281100A/en not_active Abandoned
- 2000-02-22 NZ NZ513680A patent/NZ513680A/en not_active Application Discontinuation
- 2000-02-25 AR ARP000100821A patent/AR029619A1/en not_active Application Discontinuation
- 2000-02-25 CO CO00013386A patent/CO5231139A1/en not_active Application Discontinuation
-
2001
- 2001-08-24 NO NO20014131A patent/NO20014131L/en not_active Application Discontinuation
-
2002
- 2002-04-29 HK HK02103181.1A patent/HK1043134A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1520423A (en) | 2004-08-11 |
NO20014131D0 (en) | 2001-08-24 |
AR029619A1 (en) | 2003-07-10 |
EP1155038A1 (en) | 2001-11-21 |
PL350992A1 (en) | 2003-02-24 |
MXPA01008612A (en) | 2003-06-24 |
HUP0105490A2 (en) | 2002-04-29 |
WO2000050461A1 (en) | 2000-08-31 |
HK1043134A1 (en) | 2002-09-06 |
CO5231139A1 (en) | 2002-12-27 |
CA2363641A1 (en) | 2000-08-31 |
JP2002537403A (en) | 2002-11-05 |
CZ20013081A3 (en) | 2002-02-13 |
KR20020007314A (en) | 2002-01-26 |
IL145025A0 (en) | 2002-06-30 |
HUP0105490A3 (en) | 2002-05-28 |
NZ513680A (en) | 2001-09-28 |
TR200102493T2 (en) | 2002-02-21 |
AU3281100A (en) | 2000-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20014131L (en) | Epitopes or mimotopes derived from C-epsilon-3 or C-epsilon-4 domains from IgE, antagonists thereof, and derester therapeutic applications | |
NO20053920L (en) | Preparation and treatment of demyelination diseases and paralysis in the administration of remyelination agents. | |
DE60028970D1 (en) | AT HER2 BINDING PEPTIDE COMPOUNDS | |
ATE409181T1 (en) | PROTEOMIMETIC COMPOUNDS AND METHODS | |
MA31899B1 (en) | Monoclonal antibodies are associated with hgm-csf and the medical structures they contain | |
WO2006002177A3 (en) | Interferon alpha receptor 1 antibodies and their uses | |
EA201100546A1 (en) | POLYPEPTIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS | |
BRPI0407058A (en) | Methods of prophylaxis and treatment of a disease, pharmaceutical composition, and use of a fragment | |
NO20051966L (en) | New pyrimidinamide derivatives and their use | |
CY1112376T1 (en) | 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists | |
MXPA03011499A (en) | Fce fusion proteins for treatment of allergy and asthma. | |
ATE235551T1 (en) | LIGAND (TIE LIGAND-4) FROM TIE-2 RECEPTOR AND ITS USES | |
AU6819600A (en) | Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections | |
TR200103638T2 (en) | IL-8 Receptor antagonists | |
MXPA01008613A (en) | Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses. | |
EA200702634A1 (en) | HUMANIZED ANTIBODIES SPECIFIC FOR NOGO-A AND THEIR PHARMACEUTICAL APPLICATIONS | |
EP3854875A4 (en) | Human monoclonal antibody binding specifically to human hmgb1, and pharmaceutical composition for treating or preventing alzheimer's disease containing said human monoclonal antibody | |
WO2002034288A8 (en) | Vaccine for treating allergy | |
DK1492539T3 (en) | Statin therapy to enhance cognitive function | |
WO2003092714A3 (en) | Peptide variants of ige constrained by beta-lactam bond | |
Ohanjanian et al. | An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis | |
ATE378068T1 (en) | COMBINATION OF COMPOUNDS WHICH INHIBIT THE BIOLOGICAL EFFECTS OF TNF-ALPHA AND CD95L IN ONE MEDICINAL PRODUCT | |
ATE298244T1 (en) | MONOCLONAL ANTIBODIES WITH SELECTIVE BINDING TO VGF AND USE FOR THE TREATMENT OF VGF DISEASES | |
GB2446748A (en) | Vaccine | |
JP2018510213A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |